ADRB2 and Parkinson disease: Another interesting therapeutic strategy to reduce α-Syn expression is the administration of 2-adrenergic receptor (2AR) agonists: in mice models of neurotoxin-induced parkinsonism and induced pluripotent stem cells (iPSC)-derived neuronal cultures, β2AR-agonists reduced SNCA expression, modulating gene expression through histone acetylation, and mitochondrial free radicals [84].